Clinical Research Directory

Inclusion Criteria * Discontinuous pulmonary arteries requiring conduit placement. * Normal branch pulmonary arteries, with no evidence of hypoplasia or stenosis of distal branches of pulmonary arteries, measured from the hilar pulmonary artery. * No evidence of pruning, lack of pulmonary artery lung distribution, evidence of focal stenosis, aortopulmonary collaterals or filling defects. * The proximal portion of the targeted parenchymal pulmonary artery has a minimum diameter of 4mm. * No history of systemic-pulmonary shunt placement. * Age 6 months - 2 years (to maximize direct patient benefit). * Weight \>5 kg * Values within normal range (MN Children's values, considered universal) * Participant must have biventricular heart with no hypoplasia of either the left or right ventricle. * Written informed consent obtained from a parent or legal guardian. * Caregivers must be willing and able to adhere to protocol requirements, including follow-up visits. Exclusion Criteria * Other congenital cardiac abnormalities that could interfere with graft placement or function * Allergy to bovine proteins * Allergy to aspirin * Platelet count \< 100,000 * Extra-cardiac illness that is expected to limit survival to less than 24 months * Previous operations directly involving the pulmonary arteries and/or a previous median sternotomy. * Documented coagulations disorders, patients at risk for increased risk of infection (e.g., underlying immunodeficiency including congenital arrythmia), echocardiography evidence of pulmonary hypertension, heparin-induced thrombocytopenia * Evidence of pruning, lack of pulmonary artery lung distribution, evidence of focal stenosis distal to hilum, aortopulmonary collaterals larger than hilar pulmonary artery diameter or pulmonary artery filling defects * Children with a low weight for age z score (WAZ) of less than -2. * Extraordinary obstacles to the ability to follow up regularly include homelessness, parental illness (ongoing medical care, substance abuse, mental illness), or geographical obstacles * Participation in another clinical trial involving an investigation drug, device, or intervention regardless of potential interference with this study. * Local or systemic infections will be ruled out by physical exam, vital signs, and a normal white count. * A period of 2 weeks after treatment of known infection will need to pass prior to having the conduit implanted